(1) "Approved study" means a medical research study: (a) the purpose of which is to investigate the medical benefits and risks of cannabinoid products; and (b) that is approved by an IRB.
(a) the purpose of which is to investigate the medical benefits and risks of cannabinoid products; and
(b) that is approved by an IRB.
(2) "Board" means the Cannabinoid Product Board created in Section 26-61-201.
(3) "Cannabinoid product" means the same as that term is defined in Section 58-37-3.6.
(4) "Cannabis" means the same as that term is defined in Section 58-37-3.6.
(5) "Expanded cannabinoid product" means the same as that term is defined in Section 58-37-3.6.
(6) "Institutional review board" or "IRB" means an institutional review board that is registered for human subject research by the United States Department of Health and Human Services.